Sort   by:  
 Page size 
UnknownThe effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
Not available
S-EPMC9560610 | biostudies-literature
UnknownChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.
Not available
S-EPMC9010245 | biostudies-literature
UnknownEstimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England.
Not available
S-EPMC7557299 | biostudies-literature
UnknownAntibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections.
Not available
S-EPMC8202432 | biostudies-literature
UnknownNeutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
Not available
S-EPMC8556155 | biostudies-literature
UnknownGenomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning.
Not available
S-EPMC9296497 | biostudies-literature
Sort   by:  
 Page size